Evaluation of apoptosis induced by exposure to antineoplastic drugs in peripheral blood lymphocytes of nurses

护士接触抗肿瘤药物诱发外周血淋巴细胞凋亡的评估

阅读:11
作者:Heng Liao, Lijie Bi, Jun Wei, Xin Song

Abstract

Cytostatic antineoplastic drugs are considered carcinogenic and mutagenic risk factors for health workers who are occupationally exposed to them; however, the molecular mechanisms underlying these effects remain to be elucidated. Therefore, the present study aimed to investigate the underlying mechanisms of antineoplastic drugs‑induced apoptosis of peripheral blood lymphocytes (PBLs) obtained from oncology nurses handling antineoplastic drugs. A microRNA (miRNA/miR) polymerase chain reaction (PCR) array was performed to analyze the expression levels of miRNAs in the PBLs from 3 trained nurses occupationally exposed to antineoplastic drugs. The effects of miR‑34a on cell proliferation and apoptosis in temozolomide (TMZ) treated PBLs were analyzed by cell counting kit‑8 and flow cytometry assays. The protein expression levels of B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated X protein, caspase‑3 and caspase‑9 were determined by western blot analysis, and miR‑34a expression levels were detected using quantitative reverse transcription‑PCR. The results of the present study demonstrated that miR‑34a was significantly upregulated in oncology nurses that were occupationally exposed to antineoplastic drugs. In addition, TMZ suppressed cell proliferation and induced apoptosis, by promoting the expression of miR‑34a, in a dose‑dependent manner, and also inhibited the expression of Bcl‑2. Furthermore, knockdown of miR‑34a was able to reverse the reduction of cell proliferation and promotion of apoptosis induced by TMZ in PBLs. Together, these results indicated that abnormal expression of miR‑34a may be considered a diagnostic marker in nurses occupationally exposed to antineoplastic drugs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。